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Abstract
STAT5B, a specific member of the STAT family, is intimately associated with prostate tumor
progression. While the full form of STAT5B is thought to promote tumor progression, a
naturally occurring truncated isoform acts as a tumor suppressor. We previously demonstrated that truncated STAT5 is generated by insertion of an alternatively spliced exon and
results in the introduction of an early termination codon. Present approaches targeting STAT
proteins based on inhibition of functional domains of STAT’s, such as DNA-binding, cooperative binding (protein-protein interaction), dimerization and phosphorylation will halt the
action of the entire gene, both the proto-oncogenic and tumor suppressor functions of
Stat5B.
In this report we develop a new approach aimed at inhibiting the expression of full-length
STAT5B (a proto-oncogene) while simultaneously enhancing the expression of STAT5∆B (a
tumor suppressor). We have demonstrated the feasibility of using steric-blocking
splice-switching oligonucleotides (SSOs) with a complimentary sequence to the targeted
exon-intron boundary to enhance alternative intron/exon retention (up to 10%). The functional effect of the intron/exon proportional tuning was validated by cell proliferation and
clonogenic assays. The new scheme applies specific steric-blocking splice-switching oligonucleotides and opens an opportunity for anti-tumor treatment as well as for the alteration of
functional abilities of other STAT proteins.
Key words: STAT proteins, RNA splicing, tumor suppressor, splice-switching oligonucleotides,
cell-cycle progression.

INTRODUCTION
The STAT (Signal Transducer and Activator of
Transcription) proteins are a family of cytoplasmic
transcription factors that were originally identified in
the mid-1990’s [1, 2]. To date, two predominant STAT
isoforms have been identified: a full-length transcription factor and a C-terminal truncated isoform lacking
the transactivation domain [3, 4]. We previously determined that the truncated STAT isoform is gener-

ated by retention of an alternatively spliced intron
(Figure 1), resulting in the insertion of an early termination codon [4]. The resultant STAT5∆ protein,
which lacks a transactivation domain, is then expressed. Phosphorylated STAT5∆ can translocate to
the nucleus and bind to specific promoter sequences,
thereby blocking the transcription of downstream
genes due to lack of the transactivation domain. These
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truncated isoforms have been identified for STATs 1,
3, 4, STAT 5a and 5b, and have been shown to be the
product of alternative splicing [4-6]. While at least one
group showed that STAT isoforms are a result of
post-transcriptional proteolytic cleavage, it was noted
that this event does not occur in vivo [6].
Constitutive activation of STAT5 proteins has
been demonstrated in many diverse human cancer
cell lines and clinical tumors including those of the
prostate [7-14]. A clear understanding of STAT5 function in vivo has been greatly hindered by the existence
of two nearly identical genes, STAT5A and STAT5B,
which share 93% homology at the amino acid level.
An additional complication stems from the existence
of naturally occurring C-terminal truncated dominant-negative isoforms of STAT5 [4].
Previous reports have suggested potentially diverse functions for STAT5 isoforms. Although, recent
studies provide clear evidence that STAT5B, contributes to tumor progression in epithelial cancers [11, 13,
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15, 16], especially those of the prostate [11]. Specific
activation of full-length STAT5B in epithelial cells
representing invasive and metastatic prostate cancer
has been previously demonstrated [11, 13]. This finding is consistent with STAT5 being highly activated in
high-grade human prostate cancers [9]. Increased activation of STAT5 was also associated with increasingly aggressive behavior of prostate cancer [9, 17]. In
contrast, the naturally occurring dominant-negative
truncated isoform STAT5∆B can block cell cycle progression and inhibit growth, invasive potential and
clonogenic ability (hallmark of transformed and malignant potential [18]) of cancer cell lines [11, 17, 19,
20]. Furthermore, we demonstrated that STAT5∆B
could inhibit the growth of cancer cells in grafting
studies in vivo [10, 11]. Thus, the previous research
demonstrated role of dominant-negative form of
STAT5B as tumor suppressor [11, 17, 19, 20], which
blocks cell-cycle progression.

Figure 1. Modulation of STAT5B isoforms by antisense oligonucleotides. 18m-anti and 19-anti bars above the transcripts
indicate antisense splice-switching oligonucleotides. Blue arrows represent oligonucleotides for semi-quantitative RT-PCR analysis of
splice-blocking.

http://www.biolsci.org
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Current therapeutic strategies against STAT5B
and other STAT proteins are predominantly based on
inhibiting STAT functional domains such as DNA
binding, cooperative binding (protein-protein interactions), and dimerization/phosphorylation domains.
Inhibition of these key domains not only halts proto-oncogenic functions, but also inhibits tumor suppressor actions of dominant-negative STAT5∆B,
therefore diminishing the effectiveness of the therapy.
To overcome therapeutic challenges, we developed a
novel strategy based on endogenous mechanisms
regulating STAT5B isoforms that utilizes a pro-drug
capable of converting full length STAT5B (proto-oncogenic) into the dominant negative truncated
form of STATB (tumor suppressive). Therefore we
applied specific steric-blocking splice-switching oligonucleotides (SSOs) with a complimentary sequence
to the targeted exon-intron boundary in the
pre-mRNA of Stat5B to induce alternative intron/exon retention enhancing production of tumor
suppressor protein. The SSOs complementary to exon/intron boundary sequences can block access of the
spliceosomal machinery and stimulate retention of the
associated exon [21-23]. They were used to alter
splicing for therapeutic purposes in cell line models of
human disease [21]. Splice-blocking oligonucleotides
should bind specifically to target sequence while at
the same time contain extra- or intra-molecular complementarity, have suitable solubility, and do not bind
too tightly (favoring off-target effects) or too loosely
(causing low efficacy). The SSOs must be stable in
serum, hybridize at a high melting temperature, and
form duplexes with the targeted RNA, which are not
processed by RNase H and/or other nucleases. This is
usually achieved by 2’ modification of the sugar with
O-methyl, O-methoxyethyl or O-aminopropyl groups
or by backbone modifications such as in N3’ → P5’
phosphoroamidate, peptide nucleic acids (PNAs),
phosphorodiamidate morpholino (PMO), or locked
nucleic acids (LNAs) [24-26]. PNAs offer specificity
similar to Morpholinos, but their low water solubility
makes PNA experiments difficult. Morpholino oligos
are usually soluble at several millimolar aqueous
concentrations. We have chosen to use Morpholino
oligonucleotides, which form stable base pairs with
complementary nucleic acid sequences but do not
bind proteins to a significant extent, and they mediate
RNA cleavage by RNase H or the RISC (RNA induced
silencing complex).
In this work, we also developed quantitative
PCR methodology to detect splice variants of STAT5B,
providing a feasible solution to the significant challenge of separating nearly identical truncated forms of
STAT5A and STAT5B. Here, we report evidence of the
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feasibility
of
implementing
steric-blocking
splice-switching morpholino oligonucleotides for the
modulation of STAT5B isoforms.

METHODS
Tissue Culture
Human PC-3 prostate cancer cells were obtained
from American Type Culture Collection (Manassas,
VA) and maintained in RPMI 1640 supplemented
with 10% fetal bovine serum.

Morpholino oligonucleotides and transfection
Morpholino antisense oligonucleotides (m-anti)
were purchased from Gene Tools, LLC (Philomath,
OR, USA). They were delivered into PC-3 prostate
cancer cells using Endo-Porter reagent (Gene Tools,
LLC) as per manufacturer protocol.

cDNA production
Total RNA was isolated 24 hr post-treatment and
reverse transcribed using an RNeasy Mini Kit
(QIAGEN, CA) and SuperScript®IIIRT Reverse
Transcriptase (Invitrogen, CA) according to recommended manufacturer protocols.

Sequence and analysis of DNA fragment.
Sequence of RT-PCR fragments has been performing in both directions by SeqWright DNA technology Services (Houston, TX). Alignment of sequences has been done by BLASTN 2.2.27 against
NCBI nucleotide collection.

TagMan probes for SPLICE and NONSPLICE
variants of Stat5B
Real-time PCR was performed via StepOne Real-Time PCR System (ABI) utilizing self-designed
TaqMan
hydrolysis
probes
(SPLICE
and
NONSPLICE) and TaqMan-based ABI gene expression assays (Hs99999905_m1, Gapdh). All qPCR experiments were performed in duplicate. Briefly,
cDNA samples were introduced to a MicroAmp Optical 48-well reaction plate (ABI), which was covered
with MicroAmp 48-well Optical Adhesive Film (ABI).
Each experimental well contained 20 µl total reaction
volume and included 10 µl of TaqMan Universal PCR
Master Mix (ABI), 1 µl of 20x TaqMan assay, 8 µl of
water and 1µl of analyzed sample. Self-designed 20x
assays (SPLICE and NONSPLICE) contained 16µМ
each of forward and reverse primers and 5 µМ of
TaqMan probe. The final PCR conditions were as follows: pre-heating at 50 °C for 2 min, denaturation at
95°C for 10 min and 40 cycles of amplification and
quantification (15 sec at 95 °C and 60 sec at 60 °C).
Samples were normalized using Taqman based ABI
http://www.biolsci.org
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gene expression assay Hs99999905_m1 for human
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh,
amplicon size = 122 bp).
Sequence information for designing SPLICE and
NONSPLICE splice variant primers and probes was
obtained from NCBI NG_007271.1. For this project,
SPLICE is considered a transcript variant without
introns between exons 18 and 19 while NONSPLICE
indicates the presence of the intron between exons 18
and 19. TaqManTM probes, labeled at the 5’ end with
FAM (6-carboxyfluorescein) and at the 3’ end with
TAMRA (6-carboxytetramethylrhodamine), were
synthesized via IDT. Primers and probes for TaqMan
hydrolysis qPCR assays specific for each splice variant
were designed using the Primer Express v3.0 program
(ABI). For SPLICE (Figure 1), the forward (5’CAGCGCCACGTACATGGAC -3’) and reverse (5’CGAAGTCCCCATCGGTGTC -3’) primer sequences
amplify a 75 bp region and probe (5’-FAMAGGACTGAGTCAGGGTTCTGTGGGTACATGTTA
TAGT-TAMRA-3’) were designed to span the junctions between exons 18-19. For NONSPLICE (Figure
1), the forward (5’- GGCTTTCCCCTTCCCTTCA -3’)
and reverse (5’- GAAGTCCCCATCGGTGTCAA -3’)
primer sequences amplify a 75 bp region, and probe
(5’-FAM- CTTTCCCTCCCAAGCCCTGACTCAGTC
-TAMRA-3’) was designed to span intron-19 exon
junctions. Primers and probes are specific to the input
template as no other targets were found in selected
NCBI Transcript Reference Sequences database. Duplex formation and secondary nucleic acid structures
of primer sequences were also evaluated using OligoAnalyzer 3.0 (Integrated DNA Technologies). The
analysis of primers was performed by Primer-Blast,
encompassed all homo sapien DNA sequences in the
NCBI database, and showed only one specific product
(http://blast.ncbi.nlm.nih.gov/).
To assess the efficiency of assays and assure validity of the ΔΔCT method, standard curves were
prepared for serial dilutions of input cDNA for
SPLICE, NONSPLICE and Gapdh (ABI, Hs
999999016_m1) assays. All serial dilutions of human
cDNA were prepared and run in triplicate. From the
amplification curves, CT (Cq) values for each concentration were determined and the slope of CT versus
nanograms of cDNA was used to calculate the efficiency of amplification (using StepOne software, ABI).
TaqManTM assays were linear at 6 serial dilutions of
cDNA (from 1 to 40 ng) and the efficiencies and correlation coefficients (R2) were determined by the average of 2 independent experiments. For SPLICE, the
slope was −3.16, R2 = 0.997, efficiency = 107.255, and
for NONSPLICE slope was −3.223, R2 = 0.989, and
efficiency = 104.305. For the gapdh assay (ABI, Hs

48
99999905_m1) the slope =−3.246, R2 = 0.989, efficiency
= 103.256.
In a separate validation experiment to confirm
the validity of the ΔΔCT method, standard curves
were analyzed for serial dilutions of input cDNA for
SPLICE, NONSPLICE and Gapdh. The dilution series
of cDNA containing the target gene of interest were
analyzed by qPCR. The slopes of the dilution series
were calculated by determining ΔCT between each
point on the dilution series plotted against the log of
sample (cDNA) input (mass). The rationale is that in
performing ΔΔCT analysis, no or very minimal difference in efficiencies should exist between the gene
of interest and the endogenous control (i.e. Gapdh)
[27]. For each of these assays, the efficiency and R2
values were appropriate and the slope of the line for
ΔCT of Gapdh and targets (SPLICE and NONSPLICE)
was less than 0.1. For qPCR analysis, each sample was
run in triplicate. Each run included a control lacking
template to test for contamination in assay reagents.
After a 94 0C denaturation for 10 min, reactions were
cycled 40 times with a 94 0C denaturation for 15 sec,
and a 60 0C annealing for 1 min. Three types of controls aimed at detecting genomic DNA contamination
in the RNA sample or during the RT or qPCR reactions were included: a RT mixture without reverse
transcriptase, a RT mixture including the enzyme but
no RNA, and a negative control (reaction mixture
without cDNA template). The data were collected and
analyzed using OneStep Software (ABI).

Preparation of Whole Cell Extracts
Cells were rinsed twice with ice-cold PBS (Invitrogen, Grand Island, NY), collected via cell scraper,
and suspended in radioimmunoprecipitation assay
buffer [50 mM NaF, 10 mM Na4P2O7, 0.5% sodium
deoxycholate, 0.1% SDS, 1% NP40, 150 mM NaCl, 9.1
mM Na2HPO4, and 1.7 mM NaH2PO4 (pH 7.4)] containing the following protease and phosphatase inhibitors: 1 mM Na3VO4; 1 mM phenylmethylsulfonyl
fluoride; 2 µg/ml aprotinin; 2 µg/ml antipain; 2
µg/ml leupeptin; and 2 µg/ml benzamidine. After
incubation at 4 °C for 30 min, cell extracts were isolated by centrifugation and supernatants were collected. Protein concentrations were measured using
the Bio-Rad protein assay reagent (Bio-Rad, Hercules,
CA).

Western Blot Analysis
Protein samples were separated by 7.5 %
SDS-PAGE and transferred overnight to an Odyssey
Nitrocellulose Membrane (LI-COR Biosciences). We
routinely analyzed 60 µg of total cell lysate/lane. An
antibody recognizing the amino terminus of STAT5

http://www.biolsci.org
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(N-20) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), and ß-actin (AC-74) antibody
was obtained from Sigma (St. Louis, MO, USA). After
incubation with primary antibodies, the membranes
were washed with PBS containing 0.1 % Tween 20
(PBST) thrice. Membranes were further incubated for
1 hr with IRDye800CW-conjugated goat anti-rabbit
IgG and IRDye680-conjugated goat anti-mouse IgG
secondary antibodies (LI-COR Biosciences) diluted in
Odyssey Blocking Buffer. The blots were then washed
three times with PBS-T and rinsed with PBS. Proteins
were visualized by scanning the membrane using
Odyssey Infrared Imaging System (LI-COR Biosciences) for both 700- and 800-nm wavelengths.

Cell Proliferation Assay
Cell proliferation assays were performed using
the colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxy-phenyl)-2-(4-sulfonyl)-2H-tetrazolium
assay
(CellTiter 96 AQ; Promega, Madison, WI) according to
the manufacturer’s protocol. Cells were plated in
96-well plates at a density of 2 x 103 cells/well. After
transfection with SSOs, cells were grown for 12 hr in
complete media followed by 36 hr in serum-free media.

Clonogenic Assay
24 hr after SSOs transfection in six-well plates,
PC-3 cells were counted and re-plated in 100 mm
dishes (200 cells/dish) for 10 days in complete medium. Dishes were washed once with 0.85 M NaCl,
stained with crystal violet (Sigma, St. Louis, MO,
USA) dissolved in ethanol for 15 min, and washed
well to remove excess crystal violet. Colonies containing >50 cells were scored as positive. Each experiment was performed twice in triplicates.

Statistical Analysis
Values were expressed as the mean ± SE. Statistical analyses were performed by Student’s t test for
paired comparisons using StatView program (Abacus
Concepts, Inc., Berkeley, CA, USA). Differences were
considered statistically significant at P<0.05 and all
experiments were performed independently twice or
thrice.

RESULTS
Specific intron retention in Stat5B pre-mRNA
by morpholino oligonucleotides in PC-3 cells
PC-3
cells
were
treated
with
2’-O-methyl-modified oligoribonucleoside phosphorothioate with complimentary sequence to the
targeted 5’ exon-intron boundary (18m-anti) and to
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the 3’ intron-exon boundary (19m-anti) in order to
shift splicing patterns as shown in Figure 1 at concentration of 6 uM each. The sequences of 18m-anti
and
19m-anti
oligos
are
TGCCACCTAC/
TTCTGTGGGT and GAGTCAGGG/CTTGGGAGGG
AAAGAA, respectively. Underlined is the 9 bp sequence of the 5’splice site, the slash indicates the exon-intron boundary, and conserved nucleotides of
splicing consensus are highlighted in bold. Scrambled
mispared oligonucleotide (m-mis) RyrCACrryCTrCTyrGyyr was used as a negative control; where
lower-case letters indicate mismatches, y – pyrimidine
nucleotide; and r – purine nucleotide. Antisense sequences with mismatches were appropriately distributed along the sequence to provide a stringent and
realistic assessment of sequence specificity.
Figure 2 shows the transfection of PC-3 cells with
steric-blocking splice-switching oligonucleotides. An
induced shift in splicing of Stat5b isoforms is present
(Figure 2). All targeted Morpholino oligonucleotides
generated measurable amounts of predictable product
at 559 bp confirmed by sequence analysis. These results demonstrate that the designed oligos are capable
of enhancing intron retention. Furthermore, simultaneous introduction of both 18m-anti and 19m-anti
oligos resulted in an increase of unspliced RT-PCR
products (Figure 2, lane 4), suggesting that targeting
splice-junctions blocked splicing events. Additionally,
we observed that at high concentrations, even
non-specific oligonucleotides (m-mis) cause a decrease in cell viability. RNA was isolated 24 hr
post-treatment following reverse transcription. To
validate the targeting procedure, the level and nature
of transcript alteration was characterized by reverse
transcriptase (RT)-PCR analysis of splice modification
(18ex and 19ex, Figure 1).
To validate the targeting procedure at lower
concentration of SSO treatment, we designed a protocol utilizing Quantitative Reverse Transcriptase
(RT) PCR analysis of splice modification using custom
made TaqMan probes to detect splice variants of
STAT5B (refer to Materials and Methods). This procedure detects measurable dose-dependent shift in
splicing leading to the retention of specific introns.
Next, we treated PC-3 cells with increased concentrations of an equimolar mix of 18m-anti and 19-anti.
Analysis of treated cells was performed on the total
RNA isolated 24 hr post-treatment. Figure 3 shows the
results of quantitative examination of total RNA by
RT-PCR. Results demonstrate tuning of the ratio of
non-spliced
and
spliced
forms
produced
post-incubation with morpholino oligonucleotides.
The quantity of STAT5B isoform expression and
proportion of non-spliced vs. spliced forms increased
http://www.biolsci.org
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after treatment by morpholino oligonucleotides. We
observed a dose-dependent increase in splicing retention as indicated by a shift in the ratios of the corre-
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sponding mRNA’s while mismatched oligo (m-mis)
had no effect on splicing (see Figure 3).

Figure 2. Agarose gel electrophoresis of semi-quantitative RT-PCR splice-blocking products. Splice-junctions were targeted
with two splice-blocking Morpholino oligonucleotides as described. Lane 1: m-mis; 2: 18m-anti; 3: 19m-anti; 4: combination of 18m-anti
and 19m-anti. M – 100 bp ladder. All targeted Morpholino oligonucleotides generated measurable amounts of predictable products
indicating splice retention effect. (559bp).

Figure 3. Effect of SSO’s treatment on quantity of transcription of Stat5B isoforms. The results of the analysis of total RNA
by quantitative RT-PCR. Data demonstrate tuning of the ratio of non-spliced and spliced forms produced after treatment with morpholino
oligonucleotides. Control (untreated) cells, m-mis- treatment with 600 nM mispared oligonucleotide, 30 nM, 100 nM, 300 nM, 600 nM treatment with corresponding concentration of the mix of 18m-anti and 19m-anti. Error bars indicate mean ±SD (n=3). ♦, P = 0.002; ♦♦,
P = 0.0008; ♦♦♦, P = 0.008; ♦♦♦♦, P = 0.0014; ∗, P = 0.0016; ∗∗, P =0.003; ∗∗∗, P =0.008; ∗∗∗∗, P =0.0003.

http://www.biolsci.org
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Splice regulation by the SSOs induce production of truncated dominant-negative isoform
of STAT5 protein.
To analyze functional ability of splice blocking
effects on protein expression, we performed Western
blot analysis. Total protein levels from steric-blocking
splice-switching oligonucleotide treated cells revealed
an SSO-dependent increase in STAT5∆B protein
production (Figure 4). These data are consistent with
RT-PCR results and confirm that splice retention
produces a functional transcript that can be efficiently
translated into corresponding STAT5∆B protein.

Inhibition of PC-3 cells proliferation and viability by shifting STAT5B isoform toward
truncated dominant-negative isoform.
Previously, we reported that expression of a
dominant-negative form of STAT5B reduces cell proliferation and survival by blocking cell cycle progression [10, 11]. Our aim in manipulating splice switch-
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ing to create the dominant-negative truncated form
from the full form of STAT5B is to produce a potential
tumor suppressor. We next analyzed effects of induced splice switching by SSOs on cell proliferation
and survival. We have observed dose dependent decrease of cell proliferation rate by SSOs treatment.
Quantitative analysis of cell growth was determined
by the application of different concentrations of SSOs
to tumor cells (Figure 5) and indicated that
splice-blocking oligonucleotides decrease the rate of
cell proliferation. Colony formation assays (a hallmark of transformed and malignant cell potential
[28]) revealed concentration dependent reduction of
PC-3 cell viability following SSOs treatment (Figure
6). To distinguish the toxicity of oligos to the cells
from STAT5ΔB-mediated cell growth retardation, we
treated cells with a mismatch morpholino oligonucleotide similar to SSOs but which not cause splice
retention.

Figure 4. Western Blot analyses of the splice blocking affect of morpholino oligonucleotides. Splice-junctions were targeted
with two splice-blocking morpholino oligonucleotides as described above. m-mis – 600 nM of mis-pared oligonucleotide; 600 nM 300 nM,
100 nM, and 30 nM corresponding concentration of combination of 18m-anti and 19m-anti; Un –untreated cells.

Figure 5. Treatment with splice-blocking oligonucleotides decreases cell proliferation. Control – 600 nM of mispared oligonucleotide; 600 nM, 300 nM corresponding concentration of combination of 18m-anti and 19m-anti. Error bars indicate mean ±SD
(n=3). ∗, P = 0.009; ∗∗, P =0.0115.

http://www.biolsci.org
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Figure 6. Reduction of cell survival by splice-blocking morpholino-oligonucleotides. Effect of splice blocking on cell viability as
determined via clonogenic assay. Top panel shows images of representative plates treated with 600 nM morpholino oligonucleotides while
the bottom panel quantitatively represents cell viability of SBM treated cells compared with untreated cells. M-mis - scrambled mispared
oligonucleotide was used as a negative control for cell toxicity. Error bars indicate mean ±SD (n=3). ∗, P = 0.0075; ∗∗, P =0.007.

DISCUSSION AND CONCLUDING
REMARKS
Alternative splicing is quickly gaining momentum as a viable target for molecular therapies [29].
STAT family of proteins is involved in many physiological processes and participates in inflammatory
responses and cancer progression. The problem with
current approaches of therapeutic targeting of STAT
proteins is simultaneous inhibition of opposite functions of STAT isoforms. In this work we are presenting the design of the new approach to overcome this
problem.
Splice-switching oligonucleotides are considered a novel class of therapeutics intended to induce
therapeutically favorable splice variants of targeted
genes [6]. The potential therapeutic benefit of antisense oligonucleotides has been demonstrated by
several reports [30-32]. Antisense Morpholino oligonucleotides complementary to exon/intron boundary
sequences can block access of the spliceosomal ma-

chinery and enhance alternative exon inclusion [23,
33]. The demonstrated approach focused on induction
of the specific splice retention that can occur naturally
[4]. We have demonstrated that application of Morpholino oligonucleotides to target exon-intron
boundary in the pre-mRNA of Stat5B are able to induce intron/exon retention, which was confirmed by
semi-quantitative RT-PCR. . While limited delivery
efficiency caused incomplete modification of splicing,
all targeted Morpholino oligos generated measurable
amounts of predicted target products at 559 bp (Figure 2). These results demonstrate that the designed
oligonucleotides are capable of enhancing intron retention (Figure 2). Additionally, quantitative RT-PCR
analysis confirmed a dose-dependent shift in splicing
leading to the specific intron retention (Figure 3) and
our results indicate that a modified transcript with the
additional exon can be efficiently translated into
STAT5∆B protein (Figure 4).
Expression levels of STAT5∆B protein after enhancement was still significantly lower than the full
http://www.biolsci.org
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length form. Although relative protein levels are
lower, studies have previously demonstrated that the
dominant-negative form has a significantly stronger
impact on transcriptional regulation due to a slower
rate of deactivation [4, 15]. Our cell culture data are
consistent with previously reported observation regarding the tumor suppressor activity of STAT5∆B
[10, 11]. Cell proliferation assays revealed that generation of the dominant-negative isoform of STAT5B by
splice switching SSOs leads to a dose-dependent decrease in cell proliferation (Figure 5). In addition a
clonogenic assay, which reflects the malignant potential of cancer cell lines, indicated a specific and significant reduction in prostate cancer cell viability as
induced by SSOs treatment (Figure 6).
These data demonstrate the feasibility of using
specific steric-blocking splice-switching oligonucleotides with a complimentary sequence to induce alternative intron/exon retention to convert a proto-oncogene (full length STAT5B) into a tumor suppressor (dominant-negative truncated form of
STAT5B) as a possible anti-tumor therapeutic strategy. Moreover, alternative splice-switching oligonucleotides inducing a switch from proto-oncogene to
tumor suppressor functions could potentially be used
for therapeutic tuning of other STAT proteins.
A common feature of most STATs is alternative splicing, which leads to generation of a dominant-negative isoform. STAT proteins are involved in
wide variety of physiological processes including
immune response and tumor progression. Ability to
modulate their actions and specifically switch function from tumor activating to tumor suppressing
would be highly beneficial in many areas of biomedical research. In conclusion we developed and confirmed a novel method to implement steric-blocking
splice-switching oligonucleotides for targeted delivery towards the development of novel therapeutic
strategies.
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